CLYM116 Shows Durable APRIL Suppression

Company: Climb Bio · Drug: CLYM116 · Trial Stage: Phase I (Healthy Volunteers) · Target Indication: IgA Nephropathy · Date: September 3, 2026 Summary Climb Bio reported initial Phase I healthy-volunteer data for CLYM116, a pH-dependent APRIL “sweeper” antibody licensed from Beijing Mabworks. A single…